TW202409007A - Ｔｙｋ２抑制劑之晶型及其用途 - Google Patents

Ｔｙｋ２抑制劑之晶型及其用途 Download PDF

Info

Publication number
TW202409007A
TW202409007A TW112117747A TW112117747A TW202409007A TW 202409007 A TW202409007 A TW 202409007A TW 112117747 A TW112117747 A TW 112117747A TW 112117747 A TW112117747 A TW 112117747A TW 202409007 A TW202409007 A TW 202409007A
Authority
TW
Taiwan
Prior art keywords
powder
ray diffraction
diffraction pattern
degrees
crystalline form
Prior art date
Application number
TW112117747A
Other languages
English (en)
Chinese (zh)
Inventor
考博特 百
崔維斯 瑞摩奇克
Original Assignee
美商雅盧米斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商雅盧米斯公司 filed Critical 美商雅盧米斯公司
Publication of TW202409007A publication Critical patent/TW202409007A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112117747A 2022-05-13 2023-05-12 Ｔｙｋ２抑制劑之晶型及其用途 TW202409007A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US63/341,528 2022-05-13
US202263405577P 2022-09-12 2022-09-12
US63/405,577 2022-09-12

Publications (1)

Publication Number Publication Date
TW202409007A true TW202409007A (zh) 2024-03-01

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112117747A TW202409007A (zh) 2022-05-13 2023-05-12 Ｔｙｋ２抑制劑之晶型及其用途

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
JP2025516683A (ja) 2025-05-30
CA3253365A1 (en) 2023-11-16
CL2024003456A1 (es) 2025-04-25
AU2023269081A1 (en) 2024-11-28
CN119907791A (zh) 2025-04-29
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
MX2024014000A (es) 2025-02-10
IL317011A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
EP3216790B1 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
EP2284167B1 (en) crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
JP2021504432A (ja) スルホンアミド化合物およびその使用
KR20250009492A (ko) Tyk2 억제제의 결정질 형태 및 그의 용도
WO2006024863A1 (en) Stable crystal form of imatinib mesylate and process for the preparation thereof
EP3613733A1 (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride
TW202421122A (zh) Tyk2抑制劑之晶型及其用途
WO2015011659A1 (en) Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
US20260138965A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
US20240368185A1 (en) Macrocyclic azolopyridines
JP2025535092A (ja) Ｔｙｋ２阻害剤の結晶形態及びその使用
WO2026019902A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
TW202610625A (zh) Tyk2抑制劑之晶型及其用途
TW202610624A (zh) Tyk2抑制劑之晶型及其用途
WO2026019908A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
TW202334088A (zh) 固體形式
WO2026019900A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
CN115772123A (zh) 固体形式
HK1177456B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form
HK1116783B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ME02261B (me) Postupak za pripremu atazanavir bisulfata i novih oblika